Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434465 | 1.00 | NPC1 (0.46) | NPC1RAB9AL3MBTL1OPRM1OPRL1 | |
| SCHEMBL5764293 | 0.84 | DRD2 (0.53) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL24582713 | 0.83 | NPC1 (0.54) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL1000224 | 0.83 | NPC1 (0.54) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL4442416 | 0.83 | OPRM1 (0.47) | OPRM1OPRL1 | |
| SCHEMBL3208272 | 0.83 | NPC1 (0.54) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL1150621 | 0.82 | NPC1 (0.46) | NPC1RAB9AL3MBTL1PTGDR2TMEM97 | |
| SCHEMBL31092767 | 0.81 | OPRL1 (0.41) | OPRM1OPRL1 | |
| SCHEMBL31092768 | 0.81 | OPRL1 (0.41) | OPRM1OPRL1 | |
| SCHEMBL7036798 | 0.81 | PTPN1 (0.52) | NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | GORDEEV MIKHAIL FEDOROVICH | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069441-A1 | ANTIMICROBIAL INDOLINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | IDO1, IDO2, INMT | NPC1 1168/4885RAB9A 1349/4885L3MBTL1 3059/4885 |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | NPC1 515/4885RAB9A 1343/4885L3MBTL1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.